Howard L Parnes

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140
    H L Parnes
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Plaza EPN Room 2100, Rockville MD 20852, USA
    J Clin Oncol 21:1819-24. 2003
  2. doi request reprint Prostate cancer prevention: do the 5-ARIs make the grade?
    Howard L Parnes
    National Cancer Institute, Bethesda, MD 20892, USA
    Am J Bioeth 11:30-1. 2011
  3. pmc Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer
    Yang Min Ning
    PharmD, Bldg 10 Rm 5A01, 10 Center Dr, Bethesda, MD 20892, USA
    J Clin Oncol 28:2070-6. 2010
  4. pmc Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial
    Douglas K Price
    Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
    Cancer 122:2332-40. 2016
  5. pmc Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial
    Cindy H Chau
    Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
    PLoS ONE 10:e0126672. 2015
  6. pmc Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients
    Chinonyerem Okoro
    1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    J Endourol 29:1115-21. 2015
  7. pmc Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
    William L Dahut
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    BJU Int 111:1269-80. 2013
  8. ncbi request reprint Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Eric A Klein
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH University of Texas Health Science Center at San Antonio, San Antonio, TX Fred Hutchinson Cancer Research Center, Seattle, WA University of Colorado School of Medicine, Aurora, CO SWOG Statistical Center, Seattle, WA National Cancer Institute, Bethesda, MD Division of Cancer Prevention, National Cancer Institute, Bethesda, MD VA Boston Healthcare System, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA University of Texas M D Anderson Cancer Center, Houston, TX Mayo Clinic, Rochester, MN Duke University Medical Center, Durham, NC University of California, San Diego Moores Cancer Center, La Jolla, CA London Health Sciences Centre, London, ON, Canada Swedish Cancer Institute, Seattle, WA Chao Family Comprehensive Cancer Center, Orange, CA University of Michigan, Ann Arbor, MI
    J Clin Oncol 30:7. 2012
  9. pmc Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial
    Sarah H Nash
    Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland
    Cancer Prev Res (Phila) 8:590-6. 2015
  10. pmc Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
    Sarah H Nash
    Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland
    Cancer Epidemiol Biomarkers Prev 24:1507-15. 2015

Detail Information

Publications38

  1. ncbi request reprint Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140
    H L Parnes
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Plaza EPN Room 2100, Rockville MD 20852, USA
    J Clin Oncol 21:1819-24. 2003
    ..To determine whether biochemical modulation with LV (leucovorin) enhances the efficacy of CAF (cyclophosphamide, doxorubicin, and fluorouracil) against metastatic breast cancer...
  2. doi request reprint Prostate cancer prevention: do the 5-ARIs make the grade?
    Howard L Parnes
    National Cancer Institute, Bethesda, MD 20892, USA
    Am J Bioeth 11:30-1. 2011
    ..However, to suggest that only “unambiguously safe” drugs should be approved for cancer risk reduction sets a standard that can only be met by homeopathic nostrums. That is not the standard to which we should aspire...
  3. pmc Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer
    Yang Min Ning
    PharmD, Bldg 10 Rm 5A01, 10 Center Dr, Bethesda, MD 20892, USA
    J Clin Oncol 28:2070-6. 2010
    ..These results suggest that definitive clinical trials combining antiangiogenic agent combinations with docetaxel are warranted to improve treatment outcomes for patients with metastatic CRPC...
  4. pmc Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial
    Douglas K Price
    Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
    Cancer 122:2332-40. 2016
    ....
  5. pmc Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial
    Cindy H Chau
    Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
    PLoS ONE 10:e0126672. 2015
    ..In this study, we examined the association between serum finasteride concentrations and the risk of prostate cancer in the treatment arm of the PCPT and determined factors involved in modifying drug concentrations...
  6. pmc Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients
    Chinonyerem Okoro
    1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    J Endourol 29:1115-21. 2015
    ....
  7. pmc Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
    William L Dahut
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    BJU Int 111:1269-80. 2013
    ....
  8. ncbi request reprint Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Eric A Klein
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH University of Texas Health Science Center at San Antonio, San Antonio, TX Fred Hutchinson Cancer Research Center, Seattle, WA University of Colorado School of Medicine, Aurora, CO SWOG Statistical Center, Seattle, WA National Cancer Institute, Bethesda, MD Division of Cancer Prevention, National Cancer Institute, Bethesda, MD VA Boston Healthcare System, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA University of Texas M D Anderson Cancer Center, Houston, TX Mayo Clinic, Rochester, MN Duke University Medical Center, Durham, NC University of California, San Diego Moores Cancer Center, La Jolla, CA London Health Sciences Centre, London, ON, Canada Swedish Cancer Institute, Seattle, WA Chao Family Comprehensive Cancer Center, Orange, CA University of Michigan, Ann Arbor, MI
    J Clin Oncol 30:7. 2012
    ..Longer follow-up and more prostate cancer events provide further insight into the relationship of vitamin E and prostate cancer...
  9. pmc Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial
    Sarah H Nash
    Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland
    Cancer Prev Res (Phila) 8:590-6. 2015
    ..Although, in theory, inflammation could mediate associations of serum fatty acids with prostate cancer risk, our findings cannot explain the epidemiologic associations observed with n-3 and n-6 fatty acids...
  10. pmc Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
    Sarah H Nash
    Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland
    Cancer Epidemiol Biomarkers Prev 24:1507-15. 2015
    ..This case-control study nested in the Prostate Cancer Prevention Trial evaluated associations of serum retinol and carotenoids with total, low-, and high-grade prostate cancer risk in a highly screened study population...
  11. pmc Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk
    Alan R Kristal
    Affiliations of authors Cancer Prevention Program ARK and SWOG Statistical Center AKD, CMT, PJG, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Epidemiology ARK, GEG and Department of Environmental Health GEG, University of Washington, Seattle, WA University of Missouri, Research Reactor Center, Columbia, MO JSM Harry S Truman Memorial Veterans Hospital, Columbia, MO JSM Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX IMT Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA FLM Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD LMM, HLP Moores Cancer Center, University of California San Diego, San Diego, CA SML Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH EAK
    J Natl Cancer Inst 106:djt456. 2014
    ..This case-cohort study investigates effects of selenium and vitamin E supplementation conditional upon baseline selenium status...
  12. pmc A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer
    William D Figg
    Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 183:2219-26. 2010
    ....
  13. doi request reprint Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Oncol 13:501-8. 2012
    ..We aimed to assess the safety and tolerability of ipilimumab in combination with a poxviral-based vaccine targeting prostate-specific antigen (PSA) and containing transgenes for T-cell co-stimulatory molecule expression, including CD80...
  14. doi request reprint Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions
    M Minhaj Siddiqui
    Urologic Oncology Branch MMS, AKG, RR, SRB, BJW, PAP, Molecular Imaging Program BT, PLC, Division of Cancer Prevention HLP, Laboratory of Pathology MJM, and Center for Interventional Oncology, Department of Radiology and Imaging Sciences BJW, PAP, National Cancer Institute, National Institutes of Health, Bethesda, MD Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, MD RMS Department of Surgery, Division of Urology, University of Maryland, Baltimore MD MMS Departments of Urology and Radiology, University of Alabama at Birmingham, Birmingham, AL SRB
    J Natl Cancer Inst 108:. 2016
    ..The aim of this study was to assess the biopsy efficiency of MR/ultrasound (MR/US) fusion-guided ("targeted") biopsies vs extended-sextant 12-core ("standard") biopsies for overall and high-grade prostate cancer detection...
  15. pmc Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
    BJU Int 113:254-9. 2014
    ..To examine mortality and morbidity after prostate biopsy in the intervention arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial...
  16. doi request reprint Prostate cancer prevention: agent development strategies
    Howard L Parnes
    Division of Cancer Prevention, 9609 Medical Center Drive, National Cancer Institute, Bethesda, MD, 20892 9783, USA
    Recent Results Cancer Res 202:121-31. 2014
    ....
  17. pmc Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial
    Bora Gurel
    Authors Affiliations Departments of Pathology and Immunology The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore Division of Cancer Prevention, Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, Maryland University of Colorado School of Medicine, Aurora, Colorado Department of Urology, University of Texas Health Sciences Center San Antonio, San Antonio Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas SWOG Statistical Center Cancer Prevention Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Moores Cancer Center, University of California San Diego, La Jolla, California and Division of Public Health Sciences and The Alvin J Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, St Louis, Missouri
    Cancer Epidemiol Biomarkers Prev 23:847-56. 2014
    ..Chronic inflammation is hypothesized to influence prostate cancer development, although a definitive link has not been established...
  18. ncbi request reprint Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Bamidele Adesunloye
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD U S Food and Drug Administration National Cancer Institute, Silver Spring, MD Laboratory of Tumor Immunology and Biology and Medical Oncology Branch, National Cancer Institute, Bethesda, MD National Cancer Insitute, Bethesda, MD Division of Cancer Prevention, National Cancer Institute, Bethesda, MD Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD National Cancer Institute, Rockville, MD Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC Department of Nuclear Medicine, Clinical Center, National Institutes of Health, Bethesda, MD Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD
    J Clin Oncol 30:207. 2012
    ..We hypothesized that combining lenalidomide (L), an analogue of T, with B, D, and P would have a more favorable efficacy/toxicity profile...
  19. doi request reprint Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance
    Annerleim Walton Diaz
    Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
    Urol Oncol 33:202.e1-7. 2015
    ..We evaluated the performance of multiparametric prostate magnetic resonance imaging (mp-MRI) and MRI/transrectal ultrasound (TRUS) fusion-guided biopsy (FB) for monitoring patients with prostate cancer on active surveillance (AS)...
  20. pmc Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial
    Stuart G Baker
    Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, Bethesda, MD 20892 7354, USA
    Biostatistics 11:413-8. 2010
    ..With such an important result at stake, a transparent analysis was important...
  21. doi request reprint A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma
    Andrea B Apolo
    Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Md Electronic address
    Clin Genitourin Cancer . 2016
    ..In this trial we assessed the efficacy and tolerability of TRC105, a chimeric monoclonal antibody that targets CD105 (endoglin) in patients with advanced, previously treated urothelial carcinoma (UC)...
  22. ncbi request reprint A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC)
    Fatima H Karzai
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD National Cancer Institute, Bethesda, MD Division of Cancer Prevention, National Cancer Institute, Bethesda, MD Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD National Cancer Institute, Rockville, MD
    J Clin Oncol 30:117. 2012
    ..Secondary objectives include the assessment of TRC105 pharmacokinetics, PSA response rate, evaluation of progression free survival (PFS), overall response rate (ORR) and overall survival (OS)...
  23. pmc Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer
    M Minhaj Siddiqui
    Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland7Dr Siddiqui is now with the Department of Surgery, Division of Urology, University of Maryland, Baltimore
    JAMA 313:390-7. 2015
    ..Targeted magnetic resonance (MR)/ultrasound fusion prostate biopsy has been shown to detect prostate cancer. The implications of targeted biopsy alone vs standard extended-sextant biopsy or the 2 modalities combined are not well understood...
  24. ncbi request reprint A phase II study of perifosine in androgen independent prostate cancer
    Edwin M Posadas
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Biol Ther 4:1133-7. 2005
    ..The primary objective of this study was to determine the clinical efficacy of this agent in the treatment of androgen-independent prostate cancer (AIPC) using PSA and clinical criteria...
  25. pmc TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer
    Lauren V Wood
    Vaccine Branch, Center for Cancer Research, NCI, Bethesda, MD, USA
    Oncoimmunology 5:e1197459. 2016
    ..Thus, vaccination with TARP peptides resulted in significant slowing in PSA velocity and reduction in tumor growth rate in a majority of patients with PSA biochemical recurrence. ..
  26. doi request reprint Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer
    Thomas P Frye
    Department of Urology, University of Rochester TPF, Rochester, New York Department of Urology, University of Michigan AKG, Ann Arbor, Michigan Urologic Oncology Branch TPF, AKG, AK, MM, MK, AM, HH, PAP, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Surgical Pathology MM, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Molecular Imaging Program PC, BT, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Interventional Oncology BW, PAP, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Division of Cancer Prevention HLP, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Division of Urology, University of Maryland, Baltimore, Maryland
    J Urol . 2016
    ..We evaluated multiparametric magnetic resonance imaging and magnetic resonance imaging-transrectal ultrasound fusion guided biopsy to monitor men on active surveillance...
  27. pmc Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Demetrius Albanes
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
    Cancer Prev Res (Phila) 7:886-95. 2014
    ....
  28. doi request reprint Phase III prostate cancer chemoprevention trials
    Howard L Parnes
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
    Recent Results Cancer Res 202:73-7. 2014
    ..Future studies will focus on prevention of disease progression in men on Active Surveillance, immunotherapy, mechanistically based drug combinations, and novel biomarkers of risk and benefit. ..
  29. ncbi request reprint Chemoprevention in prostate cancer
    Howard L Parnes
    Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Pharmacotherapy 26:1533; author reply 1533. 2006
  30. pmc Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial
    Douglas K Price
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Urol 184:2297-302. 2010
    ..We investigated the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer...
  31. doi request reprint Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer
    Andrea B Apolo
    Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    J Nucl Med 57:886-92. 2016
    ..This prospective pilot study evaluated the ability of Na(18)F PET/CT to detect and monitor bone metastases over time and its correlation with clinical outcomes and survival in advanced prostate cancer...
  32. doi request reprint Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib
    Rena C Zuo
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    JAMA Dermatol 151:170-7. 2015
    ....
  33. doi request reprint Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer
    Lambros Stamatakis
    Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    Cancer 119:3359-66. 2013
    ..Multiparametric prostate magnetic resonance imaging (MP-MRI) may help better select AS candidates...
  34. doi request reprint Prostate cancer prevention: strategies for agent development
    Howard L Parnes
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Curr Opin Oncol 25:242-51. 2013
    ..This article provides an update of clinical research supported by the National Cancer Institute's Phase I/II prostate cancer chemoprevention agent development program...
  35. pmc Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
    Cancer Epidemiol 36:e401-6. 2012
    ..The prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized screening trial demonstrated no mortality effect of screening. Here we analyze prostate cancer specific survival in PLCO and its relation to screening...
  36. doi request reprint Active surveillance for prostate cancer: past, present and future
    Eric A Singer
    Urologic Oncology Branch, Center for Cancer Research, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States
    Curr Opin Oncol 24:243-50. 2012
    ..This article reviews recent developments in the use of active surveillance for localized prostate cancer...
  37. ncbi request reprint Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward
    Gary J Kelloff
    National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 12:3661-97. 2006
    ....
  38. pmc Challenges in clinical prostate cancer: role of imaging
    Gary J Kelloff
    Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, National Institutes of Health, National Cancer Institute, Bethesda, MD 20852, USA
    AJR Am J Roentgenol 192:1455-70. 2009
    ..The workshop dealt with research trends and avenues for improving imaging and applications across the clinical spectrum of the disease...